IMRA Profile
IMARA Inc. (IMRA) is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of novel therapeutics for patients with rare genetic disorders. The company's pipeline includes IMR-687, a selective phosphodiesterase 9 (PDE9) inhibitor that is being developed for the treatment of sickle cell disease and beta-thalassemia.
IMR-687 is designed to improve red blood cell deformability, reduce endothelial cell activation, and inhibit inflammation, which are all important aspects of the pathophysiology of sickle cell disease and beta-thalassemia. IMARA has completed several clinical trials of IMR-687 in patients with sickle cell disease and beta-thalassemia, and the results have been promising.
In addition to IMR-687, IMARA is also developing IMR-35, a small molecule inhibitor of phosphodiesterase 5 (PDE5) for the treatment of genetic forms of pulmonary arterial hypertension (PAH) and other rare diseases. IMARA has also partnered with the biotechnology company Bristol Myers Squibb to develop and commercialize IMR-687 for the treatment of sickle cell disease and beta-thalassemia.
IMARA went public in 2019 and is traded on the NASDAQ exchange under the ticker symbol "IMRA". The company is headquartered in Boston, Massachusetts.
|
